AFT Pharmaceuticals (AFT.NZ) Stock Price
AFT Pharmaceuticals Price
AFT Pharmaceuticals (AFT.NZ) Stock | ISIN NZAFTE0001S4 | WKN A2DVUC. The current AFT Pharmaceuticals stock price is 3.94 NZD (2026). Revenue is 257.15 M NZD. Net income is 15.83 M NZD. The P/E ratio is 26.09. Market capitalization is 413.17 M NZD. AFT Pharmaceuticals operates in the Health sector.
AFT Pharmaceuticals stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of AFT Pharmaceuticals over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how AFT Pharmaceuticals stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing AFT Pharmaceuticals's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | AFT Pharmaceuticals Price |
|---|
AFT Pharmaceuticals Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
AFT Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M NZD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M NZD) |
| NET INCOME (M NZD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|
| 113 | 130 | 156 | 195 | 208 | 257 | 301 | 343 |
| 7.62 | 15.04 | 20 | 25 | 6.67 | 23.56 | 17.12 | 13.95 |
| 42.48 | 46.92 | 46.15 | 45.13 | 43.75 | 35.41 | 30.23 | 26.53 |
| 48 | 61 | 72 | 88 | 91 | 91 | 91 | 91 |
| 7 | 19 | 10 | 15 | 11 | 15 | 20 | 26 |
| -36.36 | 171.43 | -47.37 | 50 | -26.67 | 36.36 | 33.33 | 30 |
| 103.3 | 104.68 | 104.87 | 104.87 | 104.87 | 104.87 | 104.87 | 104.87 |
| – | – | – | – | – | – | – | – |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales AFT Pharmaceuticals generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue AFT Pharmaceuticals retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare AFT Pharmaceuticals's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares AFT Pharmaceuticals has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against AFT Pharmaceuticals's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
AFT Pharmaceuticals stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
AFT Pharmaceuticals Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
AFT Pharmaceuticals business model & stock analysis
AFT Pharmaceuticals SWOT Analysis
Strengths
AFT Pharmaceuticals Ltd has a strong market presence in the healthcare industry. With a wide range of pharmaceutical products and a solid customer base, the company has established itself as a trusted brand in the market.
The company possesses a diverse portfolio of products, including over-the-counter medications and prescription drugs, allowing it to cater to a broad customer base. This diversity helps the company maintain a stable revenue stream.
Weaknesses
AFT Pharmaceuticals Ltd relies heavily on a few key products for the majority of its revenue. This dependency increases the company's vulnerability to market fluctuations and potential patent expirations, which could impact its financial performance.
The company may face challenges in expanding its market share globally due to competition from established multinational pharmaceutical companies. Limited resources and reach could hinder its ability to compete effectively on a global scale.
Opportunities
AFT Pharmaceuticals Ltd can capitalize on the growing demand for healthcare products by expanding its product offerings and entering new markets. Emerging economies offer significant growth potential, as these markets continue to experience rising healthcare needs.
The increasing trend of self-medication and the shift towards preventive healthcare present opportunities for the company to develop new innovative products catering to these trends. It can also leverage advancements in technology to enhance its manufacturing and distribution processes, improving overall operational efficiency.
Threats
AFT Pharmaceuticals Ltd faces intense competition from both local and international players. The entry of new competitors or price wars can significantly impact the company's market share and profitability.
Regulatory challenges and changes in government policies related to the healthcare industry can pose threats to the company's operations, requiring compliance and adaptation to new regulations.
Economic recessions and fluctuations in exchange rates can affect the purchasing power of consumers, influencing their healthcare spending. This can potentially impact the demand for AFT Pharmaceuticals Ltd's products and services.
AFT Pharmaceuticals Eulerpool Fair Value
AFT Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio
AFT Pharmaceuticals annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
AFT Pharmaceuticals shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
AFT Pharmaceuticals Dividend History
3 years of dividend payments · 2 consecutive increases
AFT Pharmaceuticals dividend history and estimates
Max
Details
AFT Pharmaceuticals dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
AFT Pharmaceuticals shareholder structure
| % | Name |
|---|---|
69.73386% | |
7.15038% | |
0.97611% | |
0.91271% | |
0.40104% | |
0.32099% | |
0.20296% | |
0.17047% | |
0.09059% | |
0.04387% |
AFT Pharmaceuticals Executives and Management Board
Mr. Hartley Campbell Atkinson
Chief Executive Officer, Co-Founder, Executive Director · since 1997
Ms. Marree Atkinson
Co-Founder, Executive Director, Chief of Staff
Mr. David Flacks
Independent Non-Executive Chairman of the Board
Dr. Ted Witek
Non-Executive Independent Director
Mr. Malcolm Dennis Tubby
Chief Financial Officer · since 2022
Frequently asked questions about AFT Pharmaceuticals
The business model of AFT Pharmaceuticals Ltd revolves around the development, manufacturing, and marketing of pharmaceutical products. With a focus on both prescription and over-the-counter healthcare solutions, AFT Pharmaceuticals aims to improve patient outcomes and access to high-quality medicines. The company strategically targets therapeutic areas such as pain management, respiratory diseases, and allergies. By continuously innovating and leveraging its strong research and development capabilities, AFT Pharmaceuticals seeks to provide effective and affordable healthcare options for patients worldwide.
AFT Pharmaceuticals stock
AFT Pharmaceuticals Peer Group
AFT Pharmaceuticals Ticker
AFT Pharmaceuticals FIGI
All fundamentals and in-depth analysis of AFT Pharmaceuticals
Our stock analysis for AFT Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AFT Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.